Literature DB >> 19187172

Neurocognitive screening tools in HIV/AIDS: comparative performance among patients exposed to antiretroviral therapy.

S Skinner1, A J Adewale, L DeBlock, M J Gill, C Power.   

Abstract

OBJECTIVE: The aim of the study was to compare the performance of several bedside neuropsychological tools for detection of HIV-associated neurocognitive disorder (HAND) in antiretroviral drug-exposed persons.
METHODS: We analysed the relative performance of the HIV Dementia Scale (HDS), International HIV Dementia Scale (IHDS) and the Mini-Mental Status Exam (MMSE) together with neuropsychological tests (Symbol-Digit, Grooved Pegboard and Trail Making) in HIV-1-seronegative subjects (HIV-; n=13) and in HIV-1-seropositive subjects with HAND (HIV+HAND; n=13) and other neurological disorders (HIV+OND; n=20).
RESULTS: Established neuropsychological tests consistently showed significantly poorer performance by HIV+HAND subjects compared with the other two groups. Similarly, the mean HDS and IHDS scores were lower in the HIV+HAND group compared with the other two groups (P<0.005) while the mean MMSE score did not show significant differences between the HIV+HAND and HIV+OND groups. Receiver operator characteristics curves generated from these data using predefined cut-off scores revealed that the HDS, IHDS and MMSE displayed corresponding area under the curve values of 0.82, 0.74 and 0.48, respectively (P<0.006).
CONCLUSIONS: The present findings indicate that the MMSE is a weak tool for diagnosing HAND in this group of patients but the HDS and IHDS demonstrate better efficiencies, although cut-off values for the HDS require reassessment in the era of effective antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19187172     DOI: 10.1111/j.1468-1293.2008.00679.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  40 in total

1.  A Comparison of Five Brief Screening Tools for HIV-Associated Neurocognitive Disorders in the USA and South Africa.

Authors:  J A Joska; J Witten; K G Thomas; C Robertson; M Casson-Crook; H Roosa; J Creighton; J Lyons; J McArthur; N C Sacktor
Journal:  AIDS Behav       Date:  2016-08

2.  Preliminary study of a novel cognitive assessment device for the evaluation of HIV-associated neurocognitive impairment.

Authors:  Albert M Anderson; Jeffrey L Lennox; Minh L Nguyen; Drenna Waldrop-Valverde; William R Tyor; David W Loring
Journal:  J Neurovirol       Date:  2016-05-31       Impact factor: 2.643

3.  Montreal Cognitive Assessment (MoCA) for HIV-Associated Neurocognitive Disorders.

Authors:  Elena Cecilia Rosca; Loai Albarqouni; Mihaela Simu
Journal:  Neuropsychol Rev       Date:  2019-08-22       Impact factor: 7.444

Review 4.  Screening for cognitive impairment in human immunodeficiency virus.

Authors:  Victor Valcour; Robert Paul; Stephanie Chiao; Lauren A Wendelken; Bruce Miller
Journal:  Clin Infect Dis       Date:  2011-10       Impact factor: 9.079

5.  Evaluating cognitive impairment in the clinical setting: practical screening and assessment tools.

Authors:  Victor G Valcour
Journal:  Top Antivir Med       Date:  2011-12

6.  Transcriptional Regulation of CXCL5 in HIV-1-Infected Macrophages and Its Functional Consequences on CNS Pathology.

Authors:  Debjani Guha; Cynthia R Klamar; Todd Reinhart; Velpandi Ayyavoo
Journal:  J Interferon Cytokine Res       Date:  2014-12-23       Impact factor: 2.607

Review 7.  Update on HIV dementia and HIV-associated neurocognitive disorders.

Authors:  Bruce J Brew; Phillip Chan
Journal:  Curr Neurol Neurosci Rep       Date:  2014-08       Impact factor: 5.081

8.  A comparison of two post-processing analysis methods to quantify cerebral metabolites measured via proton magnetic resonance spectroscopy in HIV disease.

Authors:  Joseph Scott; Jonathan Underwood; Lucy J Garvey; Borja Mora-Peris; Alan Winston
Journal:  Br J Radiol       Date:  2016       Impact factor: 3.039

Review 9.  Recognizing cognitive and psychiatric changes in the post-highly active antiretroviral therapy era.

Authors:  Adriana Carvalhal; Jean-Guy Baril; Frederic Crouzat; Joss De Wet; Patrice Junod; Colin Kovacs; Nancy Sheehan
Journal:  Can J Infect Dis Med Microbiol       Date:  2012       Impact factor: 2.471

Review 10.  HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment.

Authors:  Phillip Chan; Bruce J Brew
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.